CN115029299B - Application of JAK2 inhibitor in islet beta cell induced differentiation - Google Patents
Application of JAK2 inhibitor in islet beta cell induced differentiation Download PDFInfo
- Publication number
- CN115029299B CN115029299B CN202210812902.XA CN202210812902A CN115029299B CN 115029299 B CN115029299 B CN 115029299B CN 202210812902 A CN202210812902 A CN 202210812902A CN 115029299 B CN115029299 B CN 115029299B
- Authority
- CN
- China
- Prior art keywords
- cells
- jak2
- islet beta
- differentiation
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title claims abstract description 65
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 title claims abstract description 40
- 230000004069 differentiation Effects 0.000 title claims abstract description 35
- RFZKSQIFOZZIAQ-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)phenyl]-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1CN(C)CCN1C1=CC=CC(NC2=NN3C=CC=C(C3=N2)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 RFZKSQIFOZZIAQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 55
- 239000002243 precursor Substances 0.000 claims description 40
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 29
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 29
- 230000009996 pancreatic endocrine effect Effects 0.000 claims description 24
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 19
- 229940043355 kinase inhibitor Drugs 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 230000024245 cell differentiation Effects 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 210000004153 islets of langerhan Anatomy 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 210000003890 endocrine cell Anatomy 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 4
- 230000001276 controlling effect Effects 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 108010075254 C-Peptide Proteins 0.000 description 13
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 10
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 description 10
- 108010076181 Proinsulin Proteins 0.000 description 10
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000007884 disintegrant Substances 0.000 description 7
- 239000012466 permeate Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 239000006186 oral dosage form Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000004114 suspension culture Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QSHGISMANBKLQL-OWJWWREXSA-N (2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[(7s)-5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl]propanamide Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C2=CC=CC=C21)=O)C(=O)CC1=CC(F)=CC(F)=C1 QSHGISMANBKLQL-OWJWWREXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000003577 pancreatic endocrine progenitor Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007660 shear property test Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
Abstract
The invention relates to the field of biotechnology, in particular to application of a JAK2 inhibitor in islet beta cell induction differentiation. The JAK2 inhibitor comprises at least one selected from CEP-33779, TG101209 and TG101348. The JAK2 inhibitor can greatly improve the differentiation efficiency of endocrine cells to islet beta cells, thereby regulating and controlling the differentiation of islet beta cells in vivo and being applied to the field of disease treatment.
Description
Technical Field
The invention relates to the field of biotechnology, in particular to application of a JAK2 inhibitor in islet beta cell induction differentiation.
Background
Diabetes is one of the main diseases affecting human health, and insulin secretion deficiency and glucose metabolism disorder caused by pancreatic endocrine beta cell function decline are important causes of diabetes, and research of functional states of islet cells is an important part while researching pathogenesis. Among them, the use of islet beta cells is an effective method for treating diabetes.
However, differentiation to obtain islet β cells requires further investigation.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems in the related art to some extent. Therefore, an object of the invention is to propose an application of a JAK2 inhibitor in the field of islet beta cell induced differentiation and an application of the JAK2 inhibitor in preparing a medicament for preventing and/or treating diabetes.
The inventors of the present invention found during the course of the study that: JAK2 inhibitors can play an important role in the process of directional differentiation of pancreatic precursor cells (Pancreatic progenitors) into islet beta cells (pancreatic beta cells), and JAK2 inhibitors can greatly improve the efficiency of differentiation of endocrine cells into islet beta cells, so that acting cells express islet beta cell specific molecular markers Proinsulin (Proinsulin), insulin (Insulin), C Peptide (C-Peptide) and NKX6.1. Therefore, the JAK2 inhibitor can regulate the directional differentiation of islet beta cells in vivo or in vitro, and can be further used for preventing or treating diseases caused by islet beta cell deficiency or abnormality.
To this end, according to a first aspect of the present invention, there is provided the use of a JAK2 inhibitor in the field of islet β cell induced differentiation. The inventors found that JAK2 inhibitors can greatly improve the differentiation efficiency of endocrine cells into islet beta cells, thereby being capable of regulating and controlling the differentiation of islet beta cells in vivo; or can be used to induce differentiation into islet beta cells in vitro for use as a specific assay.
According to an embodiment of the present invention, the above JAK2 inhibitor may further be characterized by the following technical features in the field of islet β cell induction differentiation:
in some embodiments of the invention, the JAK2 inhibitor is a JAK2 protein kinase inhibitor.
In some embodiments of the invention, the JAK2 protein kinase inhibitor comprises at least one selected from CEP-33779, TG101209, TG101348. Representative substances of JAK2 inhibitors CEP-33779, TG101209, or TG101348 can inhibit JAK2 protein kinase, so that endocrine cells or pancreatic precursor cells can be induced to differentiate into islet beta cells, and thus can be used as an induced differentiation agent or regulatory factor to mediate differentiation of islet beta cells.
In some embodiments of the invention, the JAK2 inhibitors can be used to promote the directed differentiation of pancreatic endocrine precursor cells (pancreatic endocrine progenitor) into islet beta cells. The term "pancreatic endocrine precursor cells" as used herein refers to precursor cells having the potential to differentiate to obtain islet cells, which express a specific molecular marker of pancreatic endocrine.
In some embodiments of the invention, the JAK2 inhibitor is capable of promoting the directed differentiation of pancreatic precursor cells into islet beta cells.
According to a second aspect of the present invention there is provided the use of a JAK2 inhibitor in the manufacture of a medicament for the prevention and/or treatment of diabetes. JAK2 inhibitors can greatly improve the differentiation efficiency of pancreatic endocrine precursor cells into islet beta cells, so that the differentiation of islet beta cells in vivo can be regulated, and the JAK2 inhibitors can be used for treating diseases related to islet beta cell abnormality, for example, can be used for preventing or treating diabetes.
According to an embodiment of the present invention, the use of the JAK2 inhibitor in the preparation of a medicament for preventing and/or treating diabetes may further be characterized by the following technical features:
in some embodiments of the invention, the JAK2 inhibitor is a JAK2 protein kinase inhibitor.
In some embodiments of the invention, the JAK2 protein kinase inhibitor comprises at least one selected from CEP-33779, TG101209, TG101348.
In some embodiments of the invention, the JAK2 inhibitors can be used to promote the directed differentiation of pancreatic endocrine precursor cells into islet beta cells.
In some embodiments of the invention, the JAK2 inhibitor is capable of promoting the directed differentiation of pancreatic precursor cells into islet beta cells.
In a third aspect of the invention, the invention provides a pharmaceutical composition capable of inducing differentiation of cells into islet beta cells, the pharmaceutical composition comprising a JAK2 protein kinase inhibitor.
In some embodiments of the invention, the JAK2 protein kinase inhibitor comprises at least one of CEP-33779, TG101209, TG101348.
In some embodiments of the invention, the induced differentiation of islet beta cells described above further comprises: other pharmaceutically acceptable carriers and/or excipients.
In a fourth aspect of the invention, the invention provides a kit that can be used to promote differentiation of cells into insulin β cells, the kit comprising a JAK2 inhibitor.
According to an embodiment of the invention, the cells are selected from pancreatic endocrine precursor cells or pancreatic precursor cells.
According to an embodiment of the present invention, in the kit, the JAK2 inhibitor includes at least one selected from CEP-33779, TG101209, TG101348.
In a fifth aspect of the invention, the invention provides a method of promoting differentiation of cells into islet beta cells, comprising: the cells are cultured in contact with a JAK2 inhibitor to obtain islet beta cells.
In some embodiments of the invention, the above method of promoting differentiation of cells into pancreatic β cells may further comprise the following technical features:
in some embodiments of the invention, the cell is a pancreatic endocrine precursor cell or a pancreatic precursor cell.
In some embodiments of the invention, the cells and the JAK2 inhibitor are contacted and cultured for 5 to 7 days. The cells and the JAK2 inhibitor are continuously cultured for 5-7 days, so that pancreatic endocrine precursor cells or pancreatic precursor cells can be differentiated into islet beta cells, and the expression of the islet beta cells in vivo can be regulated. Can also be used to induce cell differentiation in vitro and thus act as an inducer.
Drawings
FIG. 1 is a flow cytometric diagram of the addition of JAK2 signaling pathway-related chemical small molecule inhibitors to boost the expression levels of islet beta cell specific molecular markers Proinsulin/instrument/C-Peptide and NKX6.1, provided in accordance with an embodiment of the present invention.
Fig. 2 is a graph of a significance analysis of the production of islet beta cells with respect to the addition of a small chemical molecule inhibitor associated with the JAK2 signaling pathway, provided in accordance with an embodiment of the present invention.
Fig. 3 is a graph showing the proportion of islet beta cells obtained by continuous addition of TG101348 for 6 days according to an embodiment of the present invention.
FIG. 4 is a graph showing the increase in the rate of islet beta cell production by addition of TG101348 according to an embodiment of the present invention.
Fig. 5 shows the content ratio of each molecular marker after TG101348 is added, wherein 5a shows the content ratio of NKX6.1 and proinsulin, insulin, C peptide after TG101348 is added, and 5b shows the content ratio of NKX6.1 and C peptide after TG101348 is added.
Detailed Description
Embodiments of the present invention are described in detail below, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to like or similar elements or elements having like or similar functions throughout. The embodiments described below by referring to the drawings are illustrative and intended to explain the present invention and should not be construed as limiting the invention.
The invention discovers that a JAK2 inhibitor plays an important role in the process of directional differentiation of pancreatic precursor cells (Pancreatic progenitors) into islet beta cells (pancreatic beta cells), thereby providing an application of the JAK2 inhibitor in the field of islet beta cell induced differentiation, greatly improving the differentiation efficiency of pancreatic endocrine precursor cells into islet beta cells, and expressing islet beta cell specific molecular markers Proinsulin (Proinsulin), insulin (Insulin), C Peptide (C-Peptide) and NKX6.1.
To this end, the present invention provides the use of JAK2 inhibitors in the manufacture of a medicament for the prevention and/or treatment of diabetes. According to one embodiment of the present invention, there is provided the use of a JAK2 protein kinase inhibitor in the preparation of a medicament for the prevention and/or treatment of diabetes. According to embodiments of the present invention, the JAK2 protein kinase inhibitor may be CEP-33779, TG101209 or TG101348.JAK2 inhibitors, particularly JAK2 protein kinase inhibitors, are capable of inducing differentiation of pancreatic precursor cells or pancreatic endocrine precursor cells into pancreatic islet beta cells, thereby allowing regulation of the balance of blood glucose for the prevention or treatment of diabetes.
Herein, the term "JAK2 inhibitor" means all inhibitor substances capable of acting on the JAK2 signaling pathway, which substances are capable of inhibiting the expression of signaling molecules in the JAK2 signaling pathway.
Herein, the term "JAK2 protein kinase inhibitor" means a protein kinase capable of inhibiting the activity of JAK2 protein kinase with JAK2 protein kinase as a target. According to an embodiment of the present invention, the JAK2 protein kinase inhibitor includes at least one selected from CEP-33779, TG101209, TG101348, as shown in table 1. According to an embodiment of the present invention, the JAK2 protein kinase inhibitor is at least two selected from CEP-33779, TG101209, TG101348.
TABLE 1 Structure of chemical small molecule inhibitors related to JAK2 Signal pathway and related information
According to one embodiment of the present invention, a pharmaceutical composition comprising a JAK2 protein kinase inhibitor is provided that is capable of inducing differentiation of cells into islet beta cells.
According to embodiments of the present invention, the pharmaceutical composition further comprises other pharmaceutically acceptable carriers and/or excipients. Different excipients are used for matching with the JAK2 protein kinase inhibitor to prepare different pharmaceutical compositions, and the pharmaceutical compositions can be prepared into different dosage forms according to the purpose of administration route. Examples of routes of administration include, but are not limited to: parenteral routes, such as intravenous, intradermal, subcutaneous, intramuscular, subcutaneous, oral, buccal, sublingual, inhalation, intranasal, transdermal, topical, transmucosal, intratumoral, intrasynovial and rectal administration. In particular embodiments, the compositions are formulated in accordance with conventional methods into pharmaceutical compositions suitable for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to humans. In a specific embodiment, the pharmaceutical composition is formulated for subcutaneous administration to a human in accordance with conventional methods. Typically, the compositions for intravenous administration are solutions formulated with sterile buffers. If desired, the pharmaceutical composition may also contain a solubilizing agent and a local anesthetic to reduce pain at the injection site.
The invention also provides a pharmaceutical dosage form. Examples of such pharmaceutical dosage forms include, but are not limited to: a tablet; a caplet; capsules, such as soft elastic gelatin capsules; a cachet; a lozenge; a dispersing agent; a suppository; an ointment; a paste; a powder; a dressing agent; a cream; a plaster; a solution; a patch; aerosols (e.g., nasal sprays or inhalants); gel; liquid dosage forms suitable for oral or mucosal administration to an individual, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions); a liquid dosage form suitable for parenteral administration to an individual; a solid dosage form.
Taking an oral dosage form as an example, the pharmaceutical compositions of the present invention suitable for oral administration are presented in a dispersion dosage form, including, but not limited to: tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups). In certain embodiments, the oral dosage form is solid and is prepared with anhydrous ingredients under anhydrous conditions. Typical oral dosage forms of the invention are prepared by intimately mixing the active ingredient with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients may take a variety of forms depending on the form of formulation desired for administration. For example, excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to: water, glycol, oil, alcohols, flavoring agents, preservatives, and coloring agents. Examples of excipients suitable for use in solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to: starch, sucrose, microcrystalline cellulose, diluents, granulating agents, lubricants, binders and disintegrants.
Examples of excipients that may be used in the oral dosage form of the present invention include, but are not limited to: binders, fillers, disintegrants and lubricants. Binders suitable for use in the pharmaceutical compositions and dosage forms include, but are not limited to: corn starch, potato starch or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose), polyvinylpyrrolidone, methyl cellulose, pregelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.
Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms described herein include, but are not limited to: talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextran, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof. Disintegrants are used in the compositions of the invention to disintegrate tablets when they are contacted with an aqueous environment. Tablets containing too much disintegrant disintegrate upon storage, while tablets containing too little disintegrant do not disintegrate at the desired rate or under the desired conditions. Accordingly, an appropriate amount of disintegrant that is neither too much nor too little to adversely affect the release of the active ingredients should be used to form the solid oral dosage forms of the present invention. Disintegrants that may be used in the pharmaceutical compositions and dosage forms of the invention include, but are not limited to: agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, potassium polcalide, sodium starch glycolate, potato or tapioca starch, pregelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof. Lubricants useful in the pharmaceutical compositions and dosage forms of the present invention include, but are not limited to: calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, and mixtures thereof.
The scheme of the present invention will be explained below with reference to examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
The Insulin precursors (Proinsulin, insulin (Insulin), C Peptide (C-Peptide) and NKX6.1, where NKX6.1 is a protein expressed by the NKX6.1 gene in islet beta cells, were examined by flow cytometry using CEP-3379, TG101209 and TG101348, respectively, in suspension with pancreatic precursor cells for 6 days, followed by further culture for 8 days:
1. method for differentiating pancreatic precursor cells into pancreatic endocrine precursor cells
Suspension culture methods were used to verify differentiation of pancreatic precursor cells into pancreatic endocrine precursor cells, and cultured for 6 days. CEP-3379, TG101209 and TG101348 were added to the medium containing pancreatic precursor cells, respectively, wherein the concentration of CEP-3379 was 0.05. Mu.M, the concentration of TG101209 was 0.5. Mu.M and the concentration of TG101348 was 0.2. Mu.M.
Wherein the suspension culture plate is a low adsorption six-well plate (beavirbio, cat#40406). The medium used was: DMEM (Gibco, cat#C11965500 CP) +50x vitamin A free B-27 (Gibco, cat#12587-010) +1% glutamate (Glutamax, invitrogen, cat# 35050079) +0.25mM 2 phosphorus-L-ascorbic acid trisodium salt (Phospho-L-ascorbic acid trisodium salt) (Sigma Aldrich; cat# 49752) +10μm ALK5 inhibitor II (Enzo Life Sciences; cat#ALX-270-445-M100), triiodo-L-thyronine (5-triodo-L-thronine) (Sigma, cat#T2877) +0.1μm gamma-Secretase inhibitor XX (EMD Millipore; cat#565789-1 MG).
Wherein, the culture conditions are as follows: 37℃、5％CO 2 And 88% humidity, at 90rpm.
And (3) obtaining pancreatic endocrine precursor cells through suspension culture, and then continuously adding CEP-3379, TG101209 or TG101348 into the cells to promote differentiation of the pancreatic endocrine precursor cells into islet beta cells through suspension culture.
2. Method for differentiating pancreatic endocrine precursor cells into islet beta cells
Suspension culture methods were used to verify differentiation of pancreatic endocrine precursor cells into islet beta cells. The above pancreatic endocrine precursor cells were continuously cultured in the following medium for 8 days, and whether the pancreatic endocrine precursor cells were differentiated into islet beta cells was examined.
Among them, the suspension culture plate was a low adsorption six-well plate (beavirbio, cat#40406). The medium used was: DMEM (Gibco, cat#C11965500 CP) +50Xcontains B-27 without vitamin A (Gibco, cat#12587-010) +1% Glutamax (Invitrogen, cat# 35050079) +10. Mu.M ALK5 Inhibitor II (Enzo Life Sciences; cat#ALX-270-445-M100). Through flow cytometry detection, the islet beta cells can be obtained after culturing for 4-8 days.
3. Flow cytometry detection method
The detection methods of Insulin precursors (Proinsulin), insulin (ins), C-Peptide (C-Peptide) and NKX6.1, which are specific molecular markers of islet beta cells, are as follows:
the differentiated cell pellet was digested with pre-warmed Ackutase cell digest cell isolate (Sigma, A6964-100 ML) for 5-10 min to single cells, washed once with PBS, and fixed with 200. Mu.L of fixed permeate (Fixation and Permeabilization Solution, BD; cat # 554722) for 20min.
Then 200. Mu.L BD permeate washing solution (BD Perm/Wash TM Buffer, cat # 554723) was washed twice and incubated with primary antibody for 2 hours at 4 ℃, wherein the primary antibody was formulated as follows: 200. Mu.L BD permeate washing solution (BD Perm/Wash) TM Buffer) +1 μl murine anti-NKX6.1 (mouse anti-NKX6.1, DSHB; cat#F55A12) +1μl rabbit C peptide antibody (Rat C-pep antibody, DSHB; cat#GN-ID 4).
After the incubation, 200. Mu.L BD permeate washing (BD Perm/Wash) TM Buffer) for two times by using fluorescenceThe light secondary antibody was incubated at 4 ℃ for 1 hour in the absence of light, wherein the fluorescent secondary antibody was formulated as follows: 200 mu L BD Perm/Wash TM Buffer+monkey anti-rabbit antibody with fluorescent dye Alexa Fluor 488 (Life Technologies; cat#A-21208) (Donkey anti-Rat IgG (H+L) Secondary Antibody) +Alexa with fluorescent dye647 conjoint (Life Technologies; cat#A-31571) monkey anti-Mouse antibody (Donkey anti-Mouse IgG (H+L) Secondary Antibody).
After incubation, 200. Mu.L BD Perm/Wash was used TM Buffer washing was performed twice, followed by 200. Mu.L BD Perm/Wash TM Buffer resuspension, transfer to flow tube, detection with flow cytometer (BD Calibur), flow analysis of results with FlowJo software.
The experimental results are shown in FIG. 1. As can be seen from fig. 1, the addition of a JAK2 signaling pathway-associated small chemical molecule inhibitor effectively increased the expression levels of islet beta cell specific molecular markers, proinsulin/instrument/C-Peptide and NKX6.1 (mainly as demonstrated by the increased levels of molecular markers located in Q2 and fluorescence intensity) compared to the control. As inhibitors of JAK2, CEP-33779, tg101209 and TG101348 were all able to effectively increase the differentiation efficiency of pancreatic endocrine precursor cells into islet beta cell directed induction figure 1.
Meanwhile, the proportion of JAK2 inhibitor to generate islet beta cells in the process of promoting directional differentiation of pancreatic endocrine precursor cells to islet beta cells is remarkably analyzed, as shown in figure 2. Wherein, both TG101209 and TG101348 can obviously improve the proportion of islet beta cells.
Furthermore, we studied the case where addition of TG101348 at different time nodes induced pancreatic endocrine precursor cells to produce islet β cells. Taking TG101348 as an example, as shown in fig. 3, the ordinate in fig. 3 represents different treatment times, where "1" represents one day of treatment with TG101348, "1-2" represents two days of treatment with TG101348 added on the first day, and so on "1-3" represents three days of treatment with TG101348 added on the first day. Likewise, "2-5" represents the addition of TG101348 treatment on the next day until the fifth day. As can be seen from the results presented in fig. 3, it was found that the proportion of islet β cells obtained was highest when the treatment was continued for 6 days with TG101348.
Example 2
At the same time we assessed the effect of JAK2 inhibitors on insulin cleavage, with no JAK2 inhibitors added as controls. The insulin shear test method used was as follows:
the differentiated cell pellet was digested with pre-warmed Ackutase cell digest cell isolate (Sigma, A6964-100 ML) for 5-10 min to single cells, washed once with PBS buffer, and fixed with 200. Mu.L of fixed permeate (Fixation and Permeabilization Solution) for 20min.
Then 200. Mu.L BD permeate washing solution (BD Perm/Wash TM Buffer) was washed twice and incubated with primary antibody for 2 hours at 4 ℃, wherein primary antibody was formulated as follows: 200. Mu.L BD permeate washing solution (BD Perm/Wash) TM Buffer) +1 μl murine anti-NKX6.1 (mouse anti-NKX6.1, DSHB; cat#F55A12) +1. Mu.L of a Pig anti-C peptide antibody (Pic anti-C Peptide antibody, abcam; cat#ab 30477).
After incubation, 200. Mu.L BD Perm/Wash was used TM Buffer wash twice, incubate with fluorescent secondary antibody at 4 ℃ in the dark for 1 hour, wherein the fluorescent secondary antibody is formulated as follows: 200 mu L BD Perm/Wash TM Buffer + with fluorescent dye AlexaDonkey anti-Mouse antibody (Donkey anti-Mouse IgG (H+L) Secondary Antibody) +Alexa depictinga fluorescent dye of 488conjugate (Life Technologies; cat#A-21202)>647conjugate (Life Technologies; cat#A-21450) Goat anti-Pig antibody (gold anti-Guinea Pig IgG (H+L) Secondary Antibody).
After incubation, 200. Mu.L BD Perm/Wash was used TM Buffer washing was performed twice, followed by 200. Mu.L BD Perm/Wash TM Buffer resuspension, transfer to flow tube, and perform with flow cytometer (BD Calibur)Detection, flow result analysis was performed with FlowJo software.
As shown in the flow result diagrams in fig. 4 and 5, compared with a control, the TG101348 is added to improve the generation ratio of islet beta cells and promote the shearing of proinsulin to insulin, so that the differentiated islet beta cells tend to be more functionally mature.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (2)
- Use of a JAK2 protein kinase inhibitor for the preparation of a medicament for preventing and/or treating diabetes, the JAK2 protein kinase inhibitor promoting differentiation of pancreatic endocrine precursor cells or pancreatic precursor cells into pancreatic islet beta cells, the JAK2 protein kinase inhibitor being selected from at least one of CEP-33779, TG101209, TG101348.
- 2. A method for promoting differentiation of cells into islet beta cells for non-therapeutic purposes, comprising:culturing the cells in contact with a JAK2 inhibitor for 5-7 days to obtain islet beta cells; the JAK2 inhibitor is a JAK2 protein kinase inhibitor;the cells are pancreatic endocrine precursor cells or pancreatic precursor cells; the JAK2 protein kinase inhibitor is at least one selected from CEP-33779, TG101209 and TG101348.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210812902.XA CN115029299B (en) | 2018-11-07 | 2018-11-07 | Application of JAK2 inhibitor in islet beta cell induced differentiation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210812902.XA CN115029299B (en) | 2018-11-07 | 2018-11-07 | Application of JAK2 inhibitor in islet beta cell induced differentiation |
| CN201811317886.7A CN111154711B (en) | 2018-11-07 | 2018-11-07 | Application of JAK2 inhibitor in induced differentiation of islet beta cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811317886.7A Division CN111154711B (en) | 2018-11-07 | 2018-11-07 | Application of JAK2 inhibitor in induced differentiation of islet beta cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115029299A CN115029299A (en) | 2022-09-09 |
| CN115029299B true CN115029299B (en) | 2023-11-14 |
Family
ID=70555263
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811317886.7A Active CN111154711B (en) | 2018-11-07 | 2018-11-07 | Application of JAK2 inhibitor in induced differentiation of islet beta cells |
| CN202210812902.XA Active CN115029299B (en) | 2018-11-07 | 2018-11-07 | Application of JAK2 inhibitor in islet beta cell induced differentiation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811317886.7A Active CN111154711B (en) | 2018-11-07 | 2018-11-07 | Application of JAK2 inhibitor in induced differentiation of islet beta cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111154711B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111154711B (en) * | 2018-11-07 | 2022-08-05 | 杭州瑞普晨创科技有限公司 | Application of JAK2 inhibitor in induced differentiation of islet beta cells |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1847394A (en) * | 2005-04-15 | 2006-10-18 | 北京大学 | Method of inducing embryo stem cell to differentiate toward pancreatic cell |
| CN1982440A (en) * | 2005-07-15 | 2007-06-20 | 北京市赛诺科生物工程技术有限公司 | Cultured pancreatic cell, its culturing method and use |
| WO2008063934A2 (en) * | 2006-11-09 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Methods for differentiating insulin-producing beta cells from pancreatic precursor cells |
| TW200843776A (en) * | 2007-03-01 | 2008-11-16 | Supergen Inc | Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors |
| CN101657431A (en) * | 2007-03-01 | 2010-02-24 | 休普基因公司 | Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors |
| CN102921007A (en) * | 2011-08-09 | 2013-02-13 | 中国科学院上海生命科学研究院 | Method and reagent used for controlling insulin resistance and diabetes mellitus |
| WO2013059548A1 (en) * | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| CN104262337A (en) * | 2009-06-26 | 2015-01-07 | 加拉帕戈斯股份有限公司 | 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl Carboxamides As Jak Inhibitors |
| WO2016041906A2 (en) * | 2014-09-16 | 2016-03-24 | Technische Universität Dresden | Manipulation of hairy and enhancer of split 3 (hes3) and its regulators/mediators in diabetes, obesity, and metabolic syndrome |
| CN111154711A (en) * | 2018-11-07 | 2020-05-15 | 杭州瑞普晨创科技有限公司 | Application of JAK2 inhibitor in induced differentiation of islet β cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016015004A (en) * | 2014-05-16 | 2017-06-27 | Janssen Biotech Inc | Use of small molecules to enhance mafa expression in pancreatic endocrine cells. |
| JP7311116B2 (en) * | 2018-04-27 | 2023-07-19 | 株式会社カネカ | Method for producing pancreatic β-cells |
-
2018
- 2018-11-07 CN CN201811317886.7A patent/CN111154711B/en active Active
- 2018-11-07 CN CN202210812902.XA patent/CN115029299B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1847394A (en) * | 2005-04-15 | 2006-10-18 | 北京大学 | Method of inducing embryo stem cell to differentiate toward pancreatic cell |
| CN1982440A (en) * | 2005-07-15 | 2007-06-20 | 北京市赛诺科生物工程技术有限公司 | Cultured pancreatic cell, its culturing method and use |
| WO2008063934A2 (en) * | 2006-11-09 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Methods for differentiating insulin-producing beta cells from pancreatic precursor cells |
| TW200843776A (en) * | 2007-03-01 | 2008-11-16 | Supergen Inc | Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors |
| CN101657431A (en) * | 2007-03-01 | 2010-02-24 | 休普基因公司 | Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors |
| CN104262337A (en) * | 2009-06-26 | 2015-01-07 | 加拉帕戈斯股份有限公司 | 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl Carboxamides As Jak Inhibitors |
| CN102921007A (en) * | 2011-08-09 | 2013-02-13 | 中国科学院上海生命科学研究院 | Method and reagent used for controlling insulin resistance and diabetes mellitus |
| WO2013059548A1 (en) * | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| WO2016041906A2 (en) * | 2014-09-16 | 2016-03-24 | Technische Universität Dresden | Manipulation of hairy and enhancer of split 3 (hes3) and its regulators/mediators in diabetes, obesity, and metabolic syndrome |
| CN111154711A (en) * | 2018-11-07 | 2020-05-15 | 杭州瑞普晨创科技有限公司 | Application of JAK2 inhibitor in induced differentiation of islet β cells |
Non-Patent Citations (3)
| Title |
|---|
| Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormone-stimulated increases in cytosolic free Ca2+ and insulin secretion;Zhang Fan 等;American Journal of Physiology-Cell Physiology;第291卷(第3期);第466-475页 * |
| Janus相关激酶2基因缺失对胰岛β细胞存活及其功能的影响;何晓玉 等;中华糖尿病杂志;第9卷(第10期);第612-616页 * |
| The JAK/STAT pathway in obesity and diabetes;Esteban N.Gurzov 等;The FEBS Journal;第283卷(第16期);第3002-3015页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111154711A (en) | 2020-05-15 |
| CN115029299A (en) | 2022-09-09 |
| CN111154711B (en) | 2022-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6441867B2 (en) | Interleukin 2 superagonist and antagonist | |
| Wu et al. | Geraniol-mediated osteoarthritis improvement by down-regulating PI3K/Akt/NF-κB and MAPK signals: In vivo and in vitro studies | |
| KR20080085839A (en) | Compounds having cytokine modulating properties | |
| WO2012028688A1 (en) | Rheumatoid arthritis treatment using polyunsaturated long chain ketones | |
| US20200206231A1 (en) | Topical pharmaceutical composition, method for producing the topical pharmaceutical composition, use of topical pharmaceutical composition and method for topical treatment of psoriasis, atopic dermatitis or chronic eczema | |
| JP2022095884A (en) | Pharmaceutical composition for preventing or treating rheumatoid arthritis comprising isolated mitochondria | |
| TW201813977A (en) | Insulin analogs with reduced affinity to insulin receptor and use thereof | |
| CN104066440B (en) | Interleukin-22 purposes in treating and preventing nerve injury disease or neurodegenerative diseases | |
| Lu et al. | Isoflurane promotes epithelial-to-mesenchymal transition and metastasis of bladder cancer cells through HIF-1α-β-catenin/Notch1 pathways | |
| ES2655455T3 (en) | Compositions for the treatment of hypertension and / or fibrosis | |
| TWI288639B (en) | Treatment of emphysema using RARgamma selective retinoid agonists | |
| DE69819488T2 (en) | USE OF GLP-2 AGONISTS TO IMPROVE THE EFFECT OF THE UPPER GASTROINTESTINAL TRACT | |
| CN115029299B (en) | Application of JAK2 inhibitor in islet beta cell induced differentiation | |
| Zhang et al. | Metformin protects chondrocytes against IL-1β induced injury by regulation of the AMPK/NF-κ B signaling pathway | |
| KR20120041071A (en) | Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient | |
| Yue et al. | Excessive activation of NMDA receptor inhibits the protective effect of endogenous bone marrow mesenchymal stem cells on promoting alveolarization in bronchopulmonary dysplasia | |
| WO2022217719A1 (en) | Compound for promoting cell movement, pharmaceutical composition containing same, and preparation and use thereof | |
| WO2012112919A1 (en) | Stromal derived factor inhibition and cxcr4 blockade | |
| CN103641889A (en) | Hypoglycemic peptide and drug use thereof | |
| KR101510257B1 (en) | Diabetic renal fibrosis or tubulointersitial fibrosis inhibiting composition of chrysin | |
| WO2023137962A1 (en) | Oxidized isoaporphine alkaloid derivative, and preparation method therefor and anti-depressant use thereof | |
| CN114225006B (en) | Application of brown adipocyte secretory peptide in prevention and treatment of hypothermia diseases | |
| CN104546835A (en) | Application of 3-(benzoyl phenyl) propionic acid derivative in treatment of connexin CX31 mediated skin diseases | |
| JP2022089845A (en) | Medicament having action on anti-inflammatory bowel diseases, and preparation method therefor and applications thereof | |
| EP2578206B1 (en) | Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |